Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • Following HREC rejection, NeuroScientific Biopharma bounces back with new patent for EmtinB to treat multiple sclerosis
    Following HREC rejection, NeuroScientific Biopharma bounces back with new patent for EmtinB to treat multiple sclerosis
    • News

  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

  • Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke
    Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke
    • News

  • Paradigm’s study could give options to those with this rare incurable disease
    Paradigm’s study could give options to those with this rare incurable disease
    • News

  • Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
    Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
    • News

  • Novatti partners with Ripple for global blockchain payments network
    • News

    Novatti partners with Ripple for global blockchain payments network

    Harnessing the high speed and low cost of blockchain technology, Australian fintech and digital payments company Novatti Group (ASX: NOV) has partnered with Ripple to enable real-time remittance between Australia and Asia.  The partnership will enable Novatti to process global payments instantly through RippleNet Cloud, a blockchain payments network used by more than 300 financial

    Read More
    Public
  • Selfwealth allowing Aussies to trade US shares for $9.50 brokerage
    • News

    Selfwealth allowing Aussies to trade US shares for $9.50 brokerage

    Australians seeking to trade the world’s largest stocks like Tesla, Apple and Facebook will be able to through online share trading site Selfwealth (ASX: SWF) for low-cost flat-fee brokerage of USD $9.50 per trade.  The imminent launch on December 14 will be available to the existing 65,000 active SelfWealth clients using the same account as

    Read More
    Public
  • Cannabis sector flying high following United Nations declassification
    • News

    Cannabis sector flying high following United Nations declassification

    In a landmark decision that is tipped to normalise the use of medicinal cannabis, the United Nations has voted to remove cannabis from being a Schedule IV drug, sending the ASX cannabis sector upward in a regulatory move that will encourage individual nations to follow suit.  The UN drugs treaty was first introduced in 1961

    Read More
    Public
  • Douugh gets rolled by ASX over information leaks
    • News

    Douugh gets rolled by ASX over information leaks

    Just two months since listing on the ASX, Douugh (ASX: DOU) has drawn the ire of market regulators for information leaks to media outlets in breach of stringent listing rules. The leaks relate to the fintech company’s recently announced partnership with Humm Group (ASX: HUM) which included a $12 million capital raise as part of

    Read More
    Public
  • This app just beat 98% of dermatologists and MyFiziq are buying in
    • News

    This app just beat 98% of dermatologists and MyFiziq are buying in

    Artificial intelligence continues to emerge as the driving force behind healthcare and when pitted against 157 actual human dermatologists, this technology beat 98% of them in a diagnosis test. It’s why healthtech company MyFiziq (ASX: MYQ) is integrating it into their app. The tech itself is developed by Canadian company Triage Technology and can identify

    Read More
    Public
  • Kogan surges on to New Zealand shores with $122m eCommerce acquisition
    • News

    Kogan surges on to New Zealand shores with $122m eCommerce acquisition

    Following a proven model that skyrocketed Kogan.com (ASX: KGN) to the top of Australia’s eCommerce market, the online retailer is set to follow a similar path in New Zealand with the acquisition of Mighty Ape and its 895,000 subscribers.  A homegrown retailer in New Zealand, Mighty Ape has built a reputation for its quick delivery

    Read More
    Public
  • Summer oysters trial tipped to increase Angel Seafood sales by 15%
    • News

    Summer oysters trial tipped to increase Angel Seafood sales by 15%

    Seafood-loving Australians could soon have access to a wider range of oysters year-round with Angel Seafood (ASX: AS1) set to commence a farming trial of summer oysters which, if successful, would enable them to deliver oysters throughout the calendar year. The trials are part of Angel Seafood’s recently announced 3-pillar growth strategy to double their

    Read More
    Public
  • Rhythm Biosciences appoint mass manufacturer for bowel cancer test kits
    • News

    Rhythm Biosciences appoint mass manufacturer for bowel cancer test kits

    Aussie medtech company Rhythm Biosciences (ASX: RHY) is set to improve the screening process of colorectal cancer with manufacturing of their ColoSTAT testing kit to commence shortly after having appointed Biotem Limited as their new global manufacturer. Colorectal cancer is the third biggest cause for cancer deaths globally where current screening processes tend only to

    Read More
    Public
  • Feasibility Study confirms Syrah’s lucrative graphite facility in Louisiana
    • News

    Feasibility Study confirms Syrah’s lucrative graphite facility in Louisiana

    Amid the electric vehicle boom and growing desire from US automakers to reduce reliance on China, battery minerals company Syrah Resources (ASX: SYR) has confirmed significantly lower operating costs to supply graphite from their US facility.  The Bankable Feasibility Study (BFS) confirmed the business case for Syrah’s natural graphite Active Anode Material (AAM) production at

    Read More
    Public
  • Genetic Technologies to address mental health with pharmacogenomics AI
    • News

    Genetic Technologies to address mental health with pharmacogenomics AI

    With 1 in 8 Australians suffering from depression, the market for antidepressants is a growing one but one which medical professionals can be assisted to navigate through Genetic Technologies (ASX: GTG) and pharmacogenomics, genomic-based artificial intelligence. The tech will be coming to Australia through a new 3-year distribution agreement with Israel-based Taliaz, the developers of

    Read More
    Public
  • «
  • ‹
  • 263
  • 264
  • 265
  • 266
  • 267
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.